Drug-delivery technology market seen reaching $91.41 billion by 2030

ResearchAndMarkets.com estimates the global drug-delivery technology market will grow from $54.24 billion in 2025 to $60.27 billion in 2026, representing an 11.1% compound annual growth rate, before reaching $91.41 billion by 2030 at an 11.0% CAGR. The report links the expansion to rising chronic disease prevalence, demand for better patient compliance, growth in personalized medicine, biologics and biosimilars, and continued innovation in delivery devices and formulations. The study highlights targeted drug delivery systems, controlled and sustained-release formulations, patient-centric devices and minimally invasive technologies as major trends shaping the market. It says tariffs have raised costs for imported components, particularly in injectable and implantable segments, while also encouraging local manufacturing and more resilient supply chains. North America was the largest regional market in 2025, while Asia-Pacific is projected to be the fastest-growing region in the coming years. Leading companies cited in the report include Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc and Novartis AG. The market spans oral, injectable, topical, ocular, nasal, pulmonary, transmucosal and implantable delivery systems used across applications including cardiovascular disease, oncology, diabetes and central nervous system disorders.